Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2

Molecular Cancer Research

Volumn 7, Issue 2, 2009, Pages 275-284

  Pedersen, Nina Marie ^a   Breen, Kamilla ^a   Rødland, Marianne Skeie ^a   Haslekås, Camilla ^a   Stang, Espen ^a,b   Madshus, Inger Helene ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GELDANAMYCIN; HETERODIMER;

ARTICLE; BREAST CANCER; CANCER CELL; CELL LINE; DOWN REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BENZOQUINONES; BREAST NEOPLASMS; CELL PROLIFERATION; CROSS-LINKING REAGENTS; DIMERIZATION; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; LACTAMS, MACROCYCLIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 61349126584     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-2183     Document Type: Article

References (54)

1. Leahy DJ. Structure and function of the epidermal growth factor (EGF/ErbB) family of receptors. Adv Protein Chem 2004;68:1-27.
2. Burgess AW,Cho HS,Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003;12:541-52.
3. Harris RC,Chung E,Coffey RJ. EGF receptor ligands. Exp Cell Res 2003;284:2-13.
4. Zahnow CA. ErbB receptors and their ligands in the breast. Expert Rev Mol Med 2006;8:1 -21.
5. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
6. Klapper LN, Glathe S, Vaisman N, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A 1999;96:4995-5000.
7. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003;284:54-65.
8. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647 -55.
9. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/ neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276 -87.
10. Karunagaran D, Tzahar E, Beerli RR, et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996;15:254 - 64.
11. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341 -54.
12. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
13. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL III. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A 1994;91:8132 -6.
14. Berger MB, Mendrola JM, Lemmon MA. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett 2004;569:332-6.
15. Kim HH, Vijapurkar U, Hellyer NJ, Bravo D, Koland JG. Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem J 1998;334:189 -95.
16. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF III, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 2003;100:8933 -8.
17. Sorkin A, Von Zastrow M. Signal transduction and endocytosis: close encounters of many kinds. Nat Rev Mol Cell Biol 2002;3:600-14.
18. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 1996;271:5251 -7.
19. Baulida J, Carpenter G. Heregulin degradation in the absence of rapid receptor-mediated internalization. Exp Cell Res 1997;232:167 -72.
20. Carpenter G. ErbB-4: mechanism of action and biology. Exp Cell Res 2003;284:66-77.
21. Hommelgaard AM, Lerdrup M, van Deurs B. Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell 2004;15:1557-67.
22. Longva KE, Pedersen NM, Haslekas C, Stang E, Madshus IH. Herceptin- induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 2005;116:359 -67.
23. Wang Z, Zhang L, Yeung TK, Chen X. Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol Biol Cell 1999;10:1621-36.
24. Qiu XB, Goldberg AL. Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3. Proc Natl Acad Sci U S A 2002;99:14843 -8.
25. Diamonti AJ, Guy PM, Ivanof C, Wong K, Sweeney C, Carraway KL III. An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels. Proc Natl Acad Sci U S A 2002;99:2866 -71.
26. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002;110:669 -72.
27. Haslekas C, Breen K, Pedersen KW, Johannessen LE, Stang E, Madshus IH. The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor- ErbB2 oligomeric complexes at the plasma membrane. Mol Biol Cell 2005;16: 5832 -42.
28. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti- cancer agent: its molecular target and biochemical activity. Invest New Drugs 1999;17:361 -73.
29. Sharp S, Workman P. Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 2006;95:323-48.
30. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997;89:239 -50.
31. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999;42:260 -6.
32. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213 -7.
33. Zhou P, Fernandes N, Dodge IL, et al. ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem 2003;278:13829 -37.
34. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L. Chaperone- dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci U S A 2002;99:12847-52.
35. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996;271:22796-801.
36. Lerdrup M, Hommelgaard AM, Grandal M, van Deurs B. Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way. J Cell Sci 2006;119:85-95.
37. Pedersen NM, Madshus IH, Haslekas C, Stang E. Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent. Mol Cancer Res 2008;6:491 -500.
38. Xu W, Mimnaugh E, Rosser MF, et al. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 2001;276:3702 -8.
39. Citri A, Gan J, Mosesson Y, Vereb G, Szollosi J, Yarden Y. Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep 2004;5:1165-70.
40. Jiang X, Huang F, Marusyk A, Sorkin A. Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol Biol Cell 2003;14:858 -70.
41. Vergarajauregui S, San Miguel A, Puertollano R. Activation of p38 mitogen- activated protein kinase promotes epidermal growth factor receptor internalization. Traffic 2006;7:686 -98.
42. Whitesell L, Bagatell R, Falsey R. The stress response: implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets 2003;3:349-58.
43. Citri A, Kochupurakkal BS, Yarden Y. The Achilles heel of ErbB-2/HER2:regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 2004;3:51 -60.
44. Citri A, Alroy I, Lavi S, et al. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J 2002;21:2407-17.
45. Xu W, Yuan X, Beebe K, Xiang Z, Neckers L. Loss ofHsp90 association up-regulates Src-dependent ErbB2 activity. Mol Cell Biol 2007;27:220-8.
46. Dote H, Cerna D, Burgan WE, Camphausen K, Tofilon PJ. ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition. Cancer Res 2005;65:6967-75.
47. Tikhomirov O, Carpenter G. Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation. Cancer Res 2003;63:39-43.
48. Xu W, Yuan X, Xiang Z, Mimnaugh E, Marcu M, Neckers L. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nat Struct Mol Biol 2005;12:120-6.
49. Jiang X, Sorkin A. Epidermal growth factor receptor internalization through clathrin-coated pits requires Cbl RING finger and proline-rich domains but not receptor polyubiquitylation. Traffic 2003;4:529 -43.
50. Johansen FE, Braathen R, Brandtzaeg P. The J chain is essential for polymeric Ig receptor-mediated epithelial transport of IgA. J Immunol 2001;167:5185 -92.
51. Skarpen E, Johannessen LE, Bjerk K, et al. Endocytosed epidermal growth factor (EGF) receptors contribute to the EGF-mediated growth arrest in A431 cells by inducing a sustained increase in p21/CIP1. Exp Cell Res 1998;243:161 -72.
52. Stang E, Blystad FD, Kazazic M, et al. Cbl-dependent ubiquitination is required for progression of EGF receptors into clathrin-coated pits. Mol Biol Cell 2004;15:3591 -604.
53. Johannessen LE, Haugen KE, Ostvold AC, Stang E, Madshus IH. Heterodimerization of the epidermal-growth-factor (EGF) receptor and ErbB2 and the affinity of EGF binding are regulated by different mechanisms. Biochem J 2001;356:87-96.
54. 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res 2004;300:388 -95.